Clinical Trial

Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)

Recruiting
View on ClinicalTrials.gov →
Summary
A multi-centre observational study recruiting prospective and retrospective cohorts of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). The primary aim is to find genetic determinants of GCA and PMR susceptibility, in order to yield novel insights into disease pathogenesis. A subset of the retrospective cohort is also enrolled in a post-marketing surveillance registry of patients eligible for, or receiving tocilizumab, to treat their relapsing or refractory GCA.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2019-09-24; most recent amendment 2025-03-25.
Trial Details
NCT Number NCT04102930
Lead Sponsor University of Leeds
Collaborators: University of Oxford
Conditions Giant Cell Arteritis, Polymyalgia Rheumatica
Enrollment 4,500 participants
Start Date 2005-06-10
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-30